Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Print this page Email this page Users Online: 3984

Ahead of print publication  

Anaphylaxis and COVID-19: A clinical issue

1 Private Academic Consultant, Bangkok, Thailand
2 Dr. D.Y. Patil University, Pune, Maharashtra, India

Date of Submission19-Dec-2020
Date of Decision08-May-2022
Date of Acceptance12-May-2022

Correspondence Address:
Pathum Sookaromdee,
Private Academic Consultant, Bangkok
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/mjdrdypu.mjdrdypu_716_20

How to cite this URL:
Sookaromdee P, Wiwanitkit V. Anaphylaxis and COVID-19: A clinical issue. Med J DY Patil Vidyapeeth [Epub ahead of print] [cited 2022 Nov 30]. Available from: https://www.mjdrdypv.org/preprintarticle.asp?id=347491

Dear editor, coronavirus disease-2019 (COVID-19) is the current global medical issue. There are several clinical problems related to COVID-19. In clinical immunology, anaphylaxis and COVID-19 are an interesting issue. First, there are some reports on anaphylaxis in patients suffering from COVID-19. From root cause analysis, it is found that there is usually a cause of anaphylaxis such as antibiotics[1] or the alternative trailed COVID-19 therapy by convalescent plasma.[2] Additionally, COVID-19 outbreak results in alteration of normal medical service. Hence, the preparation for emergency telehealth care and home management of a patient with anaphylaxis during the lockdown period is necessary.[3],[4],[5]

Finally, anaphylaxis is an important consideration for new COVID-19 vaccines. In addition, anaphylaxis is a possible adverse effect of COVID-19. Although there is no report on this adverse effect of new vaccines in clinical trial reports, there are already some cases in real situations (such as in Alaska, USA). The long-term surveillance of post-launch of COVID-19 vaccines for general use is important. Skin testing might have a role in preventing anaphylaxis if the risk is high for a specific type of vaccine. According to Greenhawt et al., skin testing is important in clarifying the mechanism of anaphylaxis and providing safety advice for the next injection.[6]

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Alvarez-Perea A, Baeza ML. Anaphylactic shock following the diagnosis of coronavirus disease 2019. Ann Allergy Asthma Immunol 2020;125:477-8.  Back to cited text no. 1
Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A living systematic review. Cochrane Database Syst Rev 2020;7:CD013600.  Back to cited text no. 2
Casale TB, Wang J, Nowak-Wegrzyn A. Acute at home management of anaphylaxis during the Covid-19 pandemic. J Allergy Clin Immunol Pract 2020;8:1795-7.  Back to cited text no. 3
Senna G, Caminati M, Castells M. Editorial: Reconsidering anaphylaxis at the time of COVID-19 pandemic. Curr Opin Allergy Clin Immunol 2020;20:429-30.  Back to cited text no. 4
Mack DP, Chan ES, Shaker M, Abrams EM, Wang J, Fleischer DM, et al. Novel approaches to food allergy management during COVID-19 inspire long-term change. J Allergy Clin Immunol Pract 2020;8:2851-7.  Back to cited text no. 5
Laisuan W. COVID-19 Vaccine anaphylaxis: Current evidence and future approaches. Front Allergy 2021;2:801322. doi: 10.3389/falgy. 2021.801322.  Back to cited text no. 6


     Search Pubmed for
    -  Sookaromdee P
    -  Wiwanitkit V
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded9    

Recommend this journal